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We applaud Cronstein and Terkeltaub [1] on their
comprehensive review of the inflammatory process of gout
and its treatment. Although they allude to the fact that
colchicine probably has the smallest therapeutic window of
any drug used to treat acute gouty arthritis, they have
suggested “In treating acute gouty arthritis colchicine is
typically administered as an oral 0.6 mg dose, followed by
0.6 mg at hourly intervals until gastrointestinal side effects
(e.g. nausea, vomiting, or diarrhea) occur or a maximum total
of six to eight doses has been administered” (see also the
recommended dosage in Table 1 in [1]).
This is very similar to the dosage of colchicine suggested a
decade ago [2], and indeed comparable to the regimen that
was also expressed in grains in Hollander’s Textbook of
Rheumatology in 1960 [3]. Despite the fact that there is
perhaps only one double blind placebo controlled study on
colchicine in acute gout where gastrointestinal side effects
occurred before the relief of pain [1], and the optimal dose of
colchicine still remains elusive, there has not been any
significant change to the recommended dosage in acute gout
nearly half a century later [1]. The suggestion to administer
colchicine at frequent intervals until the development of
gastrointestinal side effects is a matter of significant concern
[4], from a practical perspective, in routine clinical practice.
Of late, a recent systematic review has shown that there is a
lack of robust data to inform the debate on the management
of a common problem such as gout and, interestingly, all of
the drugs used to treat gout can have serious side effects [5].
Indeed, Morris and colleagues [6] had suggested an effective
yet less toxic alternative regime with colchicine in the setting
of acute gout, and such anecdotal published case reports
should not be underestimated and dismissed too quickly, as
they remain a valid and efficient source for signal generation
and are of great value for drug safety.
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